Acasti Pharma Inc has a consensus price target of $4.22 based on the ratings of 4 analysts. The high is $6 issued by Craig-Hallum on February 7, 2024. The low is $2.4 issued by HC Wainwright & Co. on December 15, 2022. The 3 most-recent analyst ratings were released by Craig-Hallum, EF Hutton, and EF Hutton on February 7, 2024, February 15, 2023, and December 19, 2022, respectively. With an average price target of $3.67 between Craig-Hallum, EF Hutton, and EF Hutton, there's an implied 41.03% upside for Acasti Pharma Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Acasti Pharma (NASDAQ:ACST) was reported by Craig-Hallum on February 7, 2024. The analyst firm set a price target for $6.00 expecting ACST to rise to within 12 months (a possible 130.77% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Acasti Pharma (NASDAQ:ACST) was provided by Craig-Hallum, and Acasti Pharma initiated their buy rating.
There is no last upgrade for Acasti Pharma
There is no last downgrade for Acasti Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acasti Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acasti Pharma was filed on February 7, 2024 so you should expect the next rating to be made available sometime around February 7, 2025.
While ratings are subjective and will change, the latest Acasti Pharma (ACST) rating was a initiated with a price target of $0.00 to $6.00. The current price Acasti Pharma (ACST) is trading at is $2.60, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.